

## **Opdivo (nivolumab)**

Please provide the information below. Please print your answer, attach supporting documentation, sign, date, and return to our office as soon as possible to expedite this request. **Without this information, we may deny the request in 30 days.** 

A typed and completed *General Authorization for Information* form (13-835) must be attached to your request and must be the first page (no cover sheet).

Fax to: 1-866-668-1214

DATE OF REQUEST	PATIENT	DATE OF BIRTH	PROVIDERONE CLIENT ID
PRESCRIBER	BILLING PROVIDER NPI NUMBER	TELEPHONE NUMBER	FAX NUMBER
DRUG/STRENGTH/DOSE/FREQUENCY			
<ol> <li>What is patient's diagnosis?</li> </ol>			
☐ Metastic Melanoma			
☐ Metastic non-small cell lung cancer (NSCLC)			
Other:			
If diagnosis is non-small cell lung cancer (NSCLC), is patient EGFR or ALK positive? Yes No			
if diagnosis is non-small cell lung cancer (NSCLC), is patient LOFN of ALR positive:			
2. What other treatments have been tried?			
3. Is this prescribed for monotherapy	use?		Yes No
If no, what other anti-cancer drugs will be prescribed to use with Opdivo?			
4. For patient's who are already taking Opdivo, has patient had:			
Disease progression	1		Yes No
Unacceptable toxic	ty		Yes No
CHART NOTES DOCUMENTING THE ABOVE INFORMATION ARE REQUIRED WITH THIS REQUEST			
PRESCRIBER'S SIGNATURE	PRESCRIBER'S SPEC	CIALTY	DATE